Press releases

  28/10/2022 08:00
|

Quantum Genomics announces lack of significant efficacy for firibastat in their phase III study, FRESH and is redirecting to new developments

  26/10/2022 08:00
|

Quantum Genomics Announces the Next Meeting of its Scientific and Clinical Committee

  06/10/2022 18:00
|

Bryan Garnier and Co Initiates the Coverage of Quantum Genomics with a Target Price at 13 EUR per Share

  05/10/2022 18:00
|

Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity

  19/09/2022 07:30
|

Quantum Genomics announces that it will present the results from its phase III FRESH study on difficult-to-treat and resistant hypertension at the annual American Heart Association (AHA) conference on November 4 , 2022

  27/06/2022 18:00
|

Quantum Genomics announces the appointment of its new Scientific Advisory Board

  09/05/2022 18:00
|

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

  04/05/2022 18:00
|

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

  28/04/2022 18:00
|

Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity

  27/04/2022 08:45
|

Quantum Genomics announces successful capital raising with a gross sum of approximately EUR 15.6 M EUR

  26/04/2022 17:35
|

Quantum Genomics Raises a Gross Amount of Approximately EUR 15 M

  31/03/2022 18:00
|

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

  28/03/2022 18:00
|

Quantum Genomics Announces Granting of New Patents Protecting QGC606

  14/03/2022 18:00
|

Stéphane Cohen joins Quantum Genomics as Director of Global Operations